ArriVent BioPharma/$AVBP
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About ArriVent BioPharma
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
- Ticker
- $AVBP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Newtown Square, United States
- Website
- arrivent.com
AVBP Metrics
BasicAdvanced
$676M
-
-$3.67
1.66
-
Price and volume
Market cap
$676M
Beta
1.66
52-week high
$35.83
52-week low
$11.36
Average daily volume
2.1M
Financial strength
Current ratio
17.643
Quick ratio
16.653
Total debt to equity
0.001
Profitability
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-3,399.38%
Operating margin (TTM)
-3,620.00%
Management effectiveness
Return on assets (TTM)
-30.42%
Return on equity (TTM)
-48.67%
Valuation
Price to revenue (TTM)
121.042
Price to book
1.7
Price to tangible book (TTM)
1.7
Price to free cash flow (TTM)
-3.96
Free cash flow yield (TTM)
-25.25%
Free cash flow per share (TTM)
-3.301
Growth
Earnings per share change (TTM)
-12.10%
3-year earnings per share growth (CAGR)
-51.85%
What the Analysts think about AVBP
Analyst ratings (Buy, Hold, Sell) for ArriVent BioPharma stock.
Analyst projections of the future price of ArriVent BioPharma stock.
Bulls say / Bears say
Phase 1 data suggest firmonertinib may still have potential in PACC-mutant lung cancer, a distinct setting from the failed FURVENT trial. At 240 mg, previously untreated patients had a 68% confirmed response rate and median progression-free survival of 16 months; a Phase 3 trial is under way. (MD Anderson Cancer Center, SEC)
ARR-217 offers a second clinical opportunity: in an early study, 29 pre-treated colorectal cancer patients at the 6 mg/kg dose had a 44.8% response rate and a 93.1% disease control rate. The results are preliminary, with dose optimisation still under way. (GlobeNewswire)
ArriVent reported $373.1 million in cash and investments at the end of June, which it expects to fund operations into 2028. That gives it time to advance its remaining clinical programmes after the FURVENT setback. (ArriVent BioPharma)
Firmonertinib failed FURVENT’s primary endpoint. Independent reviewers found median progression-free survival of 11 months at the higher dose versus 9.5 months with chemotherapy, a difference that was not statistically significant. (GlobeNewswire)
Competition in first-line EGFR exon 20 lung cancer is intensifying. Taiho and Cullinan reported that zipalertinib plus chemotherapy met its Phase 3 primary endpoint, while other targeted treatments are already on the market. (BioPharma Dive)
The company has no product sales and used $81.5 million in operating cash in the first half of 2026. It raised $140 million by selling 5.36 million shares through its at-the-market programme during that period, highlighting the risk of further dilution as it funds development. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 26 Oct 2026.
AVBP Financial Performance
Revenues and expenses
AVBP Earnings Performance
Company profitability
Upcoming events
No upcoming events
AVBP News
AllArticlesVideos
Aarvik Therapeutics Announces Milestone Achievement, Partnership Update, and Presentations on MUTTA™ and AQUALINK™ Platforms at the 17th Annual WADC Conference
Business Wire2 weeks ago
Arrivent Biopharma Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your AVBP Investments
Newsfile Corp2 weeks ago
ArriVent BioPharma's ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study
MarketBeat2 weeks ago
Funds containing AVBP
Fund name | Fund size | $AVBP weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.04% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.02% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.